Floatz logo

Tesamorelin

Growth Hormone Deficiency

Columbia Universityprotein_peptidePhase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Growth Hormone Deficiency cohort.

Asset / SponsorPhaseRating
Genotropin
University of Calgary
Phase 4BBB
Omnitrope
University Hospital, Toulouse
Phase 4BB
Growth Hormone Releasing Hormone 1-44
Massachusetts General Hospital
Phase 2B
ADVICOR COMPONENT NIACIN
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 1/2CCC
Recombinant Gh Saizen
Federico II University
Phase 3NR

Same molecule, other indications

Tesamorelin is also rated in:

lipodystrophyDormant
B
Indicative ·
62 / 100
View asset →
Body CompositionDormant
B
Indicative ·
60 / 100
View asset →
HIV infectious diseaseDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →